ATE217193T1 - Verwendung von spezifischen rxr-rezeptorliganden - Google Patents

Verwendung von spezifischen rxr-rezeptorliganden

Info

Publication number
ATE217193T1
ATE217193T1 AT96401140T AT96401140T ATE217193T1 AT E217193 T1 ATE217193 T1 AT E217193T1 AT 96401140 T AT96401140 T AT 96401140T AT 96401140 T AT96401140 T AT 96401140T AT E217193 T1 ATE217193 T1 AT E217193T1
Authority
AT
Austria
Prior art keywords
specific
ligand
receptor ligands
rxr receptor
specific rxr
Prior art date
Application number
AT96401140T
Other languages
English (en)
Inventor
Michel Demarchez
Andre Jomard
Original Assignee
Galderma Rech Dermatologique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Rech Dermatologique filed Critical Galderma Rech Dermatologique
Application granted granted Critical
Publication of ATE217193T1 publication Critical patent/ATE217193T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT96401140T 1995-06-19 1996-05-28 Verwendung von spezifischen rxr-rezeptorliganden ATE217193T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9507300A FR2735367B1 (fr) 1995-06-19 1995-06-19 Utilisation de ligands specifiques des recepteurs rxrs

Publications (1)

Publication Number Publication Date
ATE217193T1 true ATE217193T1 (de) 2002-05-15

Family

ID=9480139

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96401140T ATE217193T1 (de) 1995-06-19 1996-05-28 Verwendung von spezifischen rxr-rezeptorliganden

Country Status (11)

Country Link
US (1) US6004987A (de)
EP (1) EP0749752B1 (de)
JP (1) JP2804014B2 (de)
AT (1) ATE217193T1 (de)
AU (1) AU688216B2 (de)
CA (1) CA2179426A1 (de)
DE (1) DE69621076T2 (de)
DK (1) DK0749752T3 (de)
ES (1) ES2179168T3 (de)
FR (1) FR2735367B1 (de)
PT (1) PT749752E (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2753091B1 (fr) * 1996-09-09 2001-03-16 Oreal Utilisation d'un agoniste des recepteurs des retinoides de type rxr pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
EP1019059A4 (de) * 1997-01-24 2004-01-14 Univ California Verwendung von fxr, ppar-alpha- und lxr-alpha-aktivatoren zur wiederherstellung der barrierefunktion, zur förderung der epidermisdifferenzierung, und zur proliferationshemmung
AU6895198A (en) * 1997-04-11 1998-11-11 Sidney Kimmel Cancer Center Retinoid related molecules for the inhibition of endothelin-1 overproduction in disease
FR2767058B1 (fr) * 1997-08-05 2000-05-05 Centre Nat Rech Scient Utilisation d'un compose de type retinoide, notamment l'acide retinoique pour la preparation d' un medicament destine au traitement de l'obesite.
EP0908179A1 (de) * 1997-08-23 1999-04-14 Werner Bollag Behandlung von zellvermittelten Immunkrankheiten
US8541469B2 (en) * 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
US20030113281A1 (en) * 1998-05-06 2003-06-19 Galderma Research & Development, S.N.C. Assay for identification of compounds that promote melanin production and retinoid-like compounds identified by said assay
IL138772A0 (en) * 1998-05-06 2001-10-31 Galderma Res & Dev Assay for identification of compounds that promote melanin production and retinoid-like compounds identified by said assay
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
MXPA01012494A (es) 1999-06-01 2002-07-02 Univ Texas Southwestern Med Ct Metodo para tratar perdida capilar con el uso de compuestos sulfonil tiromimeticos.
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
CA2374266A1 (en) * 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
JP2003500432A (ja) * 1999-06-01 2003-01-07 ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター ジフェニルエーテル誘導体を用いて脱毛症を処置する方法
US6436993B1 (en) * 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
US20060079490A1 (en) * 2001-01-25 2006-04-13 Deluca Hector F Method of treatment of type I diabetes
US20030018017A1 (en) * 2001-01-25 2003-01-23 Deluca Hector F. Method of treatment of type I diabetes
JP4473491B2 (ja) * 2002-05-28 2010-06-02 株式会社資生堂 毛穴縮小剤
JP2004020220A (ja) * 2002-06-12 2004-01-22 Pioneer Electronic Corp 通信システム及び方法、通信端末装置、通信センタ装置、並びにコンピュータプログラム
US20050202055A1 (en) * 2004-03-11 2005-09-15 Koichi Shudo, Tokyo, Japan Anti-wrinkle agent
US20090281184A1 (en) * 2005-09-27 2009-11-12 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by in-crease in vasopermeability
CN116283698B (zh) * 2023-02-28 2026-03-20 慧合谷(上海)生物科技有限公司 一种全反式维a酸苯甲基酯及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2129115T3 (es) * 1993-01-11 1999-06-01 Ligand Pharm Inc Compuestos que tienen actividad selectiva para los receptores de retinoides x, y medios para la modulacion de procesos mediados por receptores de retinoides x.
WO1994015901A1 (en) * 1993-01-11 1994-07-21 Ligand Pharmaceuticals Inc. Compounds having selectivity for retinoid x receptors
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
FR2722985B1 (fr) * 1994-07-27 1996-09-13 Cird Galderma Nouvelles compositions a base d'un melange synergetique entre au moins un ligand specifique des rxrs et au moins un ligand specifique de rar-x ou de vdr, et leurs utilisations

Also Published As

Publication number Publication date
US6004987A (en) 1999-12-21
PT749752E (pt) 2002-08-30
DE69621076T2 (de) 2002-08-29
CA2179426A1 (fr) 1996-12-20
JPH092972A (ja) 1997-01-07
JP2804014B2 (ja) 1998-09-24
ES2179168T3 (es) 2003-01-16
EP0749752A1 (de) 1996-12-27
DE69621076D1 (de) 2002-06-13
FR2735367B1 (fr) 1997-07-18
EP0749752B1 (de) 2002-05-08
FR2735367A1 (fr) 1996-12-20
AU688216B2 (en) 1998-03-05
AU5470396A (en) 1997-01-16
DK0749752T3 (da) 2002-08-26

Similar Documents

Publication Publication Date Title
DE69621076D1 (de) Verwendung von spezifischen RXR-Rezeptorliganden
DE69228325D1 (de) Ligandentest unter verwendung von interferenzmodulation
DE69123604D1 (de) Elektrophoretische anzeigetafel unter verwendung von graustufenfähigkeit mit flächenmodulation
DE69535095D1 (de) Vorrichtung zum austeilen von gebrauchsfertiger visköser lösung sowie deren verwendung zum austeilen
DK0831769T3 (da) Hidtil ukendte anvendelser af thyroideahormoner eller thyroideahormon-lignende forbindelser
DE68907538D1 (de) Zeile-pro-zeile-ansteuerverfahren einer plasmaanzeigetafel vom wechselspannungsbetriebenen typ mit koplanarer unterstuetzung.
FI944735L (fi) Nisäkkään melanosyyttejä stimuloivan hormonin reseptoreita ja käyttö
DE69736385D1 (de) Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen
PE20000028A1 (es) Aplicadores
DE3775586D1 (de) Bituminoese zusammensetzung und ihre verwendung als kalt auftrabarer haftklebstoff.
NO933860D0 (no) Ekstracellulaere matriks-reseptorligander som modulerer leukocyttfunksjon
ATE55730T1 (de) Druckempfindliches aufzeichnungsmaterial.
DK239886D0 (da) Arrangement til bestemmelse af graden af konsistens hos en egenskabfor et omraade i et i diskrete billedelementer opdelt billede
DE69500085D1 (de) Synergistische Mischung mindestens eines RXR-spezifischen Liganden mit mindestenseinem RAR-Alpha spezifischen Liganden
NO870923L (no) Apparat for styring av lasthaandteringsposisjon.
DE68914912D1 (de) Flüssigkristallzusammensetzung und deren Verwendung.
SE9904586D0 (sv) Sätt vid bestrykning av en löpande bana samt anordning
DK603387D0 (da) Apparat til paafoersel af et sejtflydende taetningsmateriale i ringform paa en i det vaesentlige plan overflade, fortrinsvis paa et daaselaag
DE69318498D1 (de) Entwickler vom Ascorbinsäure-Typ und mit einer bestimmten Zusammensetzung
DE69308302D1 (de) Klebstoffe für das beschichten von zahlreichen substraten mit vinyl
DE59804819D1 (de) Katalysatorzubereitung für die (co)polymerisation von alk-1-enen
DE69000986D1 (de) Verbindung von reibmaterial mit beschichtetem grundkoerper.
DK161208C (da) Perforeret bituminoest taglaegningsmateriale indeholdende en metalfolie samt fremgangsmaade og apparat til fremstilling heraf.
DE68919786D1 (de) Geruchlose von polyvalenten Metallen modifizierte Salizylsäurecopolymere, deren Herstellungsverfahren und ihre Verwendung als Farbentwicklungsmittel für druckempfindliche Aufzeichnungspapierschichten.
DE3882967D1 (de) Verfahren zum steuern von einem anzeigegeraet mit flachem bildschirm und anzeigegeraet mit flachem bildschirm.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee